US · BLLN · MEDICAL - DIAGNOSTICS & RESEARCH
BillionToOne, Inc. (BLLN) intrinsic value and stock valuation
$89.92as of 2026-11-21 · Mkt cap 6.9B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
BillionToOne, Inc. DCF and intrinsic value
InvestorsCraft values BLLN with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from BLLN’s statements →
BillionToOne, Inc. Graham Number
Graham Number: $6.19d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2023–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $305.1M | $152.6M | $71.7M |
| Operating income | $16M | -$-47.15M | -$-69.5M |
| Net income | $7.45M | -$-41.57M | -$-82.68M |
| EPSd | $162.7K | -$-929.56K | -$-1.85M |
| Operating cash flow | $24.6M | -$-41.38M | -$-53.67M |
| Capital expenditure | -$-8.88M | -$-5.4M | -$-6.17M |
| Free cash flow | $15.7M | -$-46.78M | -$-59.85M |
| Total assets | $632.7M | $302.1M | $191.7M |
| Total debt | $108.9M | $109.4M | $146.4M |
| Net debt | -$-387.08M | -$-82.1M | $49.1M |
| Total equity | $480.1M | $167.8M | $30.5M |
| Cash and short-term investments | $496M | $191.5M | $97.3M |
Income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $305.1M | $152.6M | $71.7M |
| Cost of revenue | $96.7M | $71.7M | $54.4M |
| Gross profit | $208.5M | $80.9M | $17.3M |
| Research and development expenses | $49.4M | $36.6M | $22.4M |
| Selling, general and administrative expenses | $143.1M | $91.5M | $64.4M |
| Other expenses | $0.00 | $0.00 | $0.00 |
| Operating expenses | $192.4M | $128.1M | $86.8M |
| Cost and expenses | $289.1M | $199.7M | $141.2M |
| Interest income | $7.75M | $5.82M | $3.46M |
| Interest expense | $100K | $2.39M | $3.27M |
| Depreciation and amortization | $11.9M | $11.7M | $6.46M |
| Ebitda | $19.8M | -$-27.47M | -$-72.94M |
| Operating income | $16M | -$-47.15M | -$-69.5M |
| Total other income/expenses, net | -$-8.26M | $5.61M | -$-13.18M |
| Income before tax | $7.76M | -$-41.54M | -$-82.67M |
| Income tax expense | $300K | $30K | $10K |
| Net income | $7.45M | -$-41.57M | -$-82.68M |
| Weighted average shares outstanding | $45.8M | $44.7M | $44.7M |
| Weighted average diluted shares outstanding | $45.8M | $44.7M | $44.7M |
Balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Cash and short-term investments | $496M | $191.5M | $97.3M |
| Net receivables | $41.6M | $24.7M | $9.09M |
| Inventory | $17.6M | $8.73M | $7.2M |
| Total current assets | $560.6M | $227.8M | $115.5M |
| Property, plant and equipment, net | $67.1M | $68.9M | $73.9M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $72.1M | $74.2M | $76.2M |
| Total assets | $632.7M | $302.1M | $191.7M |
| Accounts payable | $7.18M | $4.3M | $3.21M |
| Short-term debt | $5.6M | $6.22M | $53.7M |
| Deferred revenue | $2.19M | $2.81M | $3.02M |
| Total current liabilities | $48M | $28.4M | $66.8M |
| Long-term debt | $103.3M | $103.2M | $92.6M |
| Deferred revenue, non-current | $1.29M | $0.00 | $0.00 |
| Total non-current liabilities | $104.6M | $105.9M | $94.4M |
| Capital lease obligations | $46.1M | $51.7M | $57.6M |
| Total liabilities | $152.6M | $134.3M | $161.2M |
| Common stock | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-274.75M | -$-282.2M | -$-240.63M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 |
| Total equity | $480.1M | $167.8M | $30.5M |
| Total investments | $0.00 | $0.00 | $0.00 |
| Total debt | $108.9M | $109.4M | $146.4M |
| Net debt | -$-387.08M | -$-82.1M | $49.1M |
Cash flow statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Net income | $2.92M | -$-41.57M | -$-82.68M |
| Depreciation and amortization | $11.9M | $11.7M | $7M |
| Stock-based compensation | $15.9M | $8.36M | $4.85M |
| Change in working capital | -$-22.05M | -$-16.77M | $3.79M |
| Accounts receivable | -$-16.91M | -$-15.62M | -$-2.59M |
| Inventory | -$-8.81M | -$-1.53M | -$-1.41M |
| Accounts payable | $1.77M | $880K | $150K |
| Net cash provided by operating activities | $24.6M | -$-41.38M | -$-53.67M |
| Investments in property, plant and equipment | -$-8.92M | -$-5.4M | -$-6.17M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-8.92M | -$-5.43M | $82.8M |
| Common stock issued | $290.6M | $131.1M | $440K |
| Common stock repurchased | $0.00 | -$-550K | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $288.8M | $141M | $13.4M |
| Net change in cash | $304.5M | $94.2M | $97.3M |
| Cash at end of period | $496M | $191.5M | $97.3M |
| Operating cash flow | $24.6M | -$-41.38M | -$-53.67M |
| Capital expenditure | -$-8.88M | -$-5.4M | -$-6.17M |
| Free cash flow | $15.7M | -$-46.78M | -$-59.85M |
Line items
Line items
Line items
About BillionToOne, Inc.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
- CEO
- Oguzhan Atay
- Employees
- 713
- Beta
- 0.34
Explore
Frequently asked questions
What is the intrinsic value of BillionToOne, Inc. (BLLN)?
BillionToOne, Inc. (BLLN) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is BLLN undervalued?
BLLN trades at a price of $89.92 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.